Dr Reddy's Laboratories (Dr Reddy's Laboratories) Debt-to-Equity

: 0.07 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Dr Reddy's Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $165 Mil. Dr Reddy's Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $74 Mil. Dr Reddy's Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3,217 Mil. Dr Reddy's Laboratories's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dr Reddy's Laboratories's Debt-to-Equity or its related term are showing as below:

RDY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.26 Max: 0.53
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Dr Reddy's Laboratories was 0.53. The lowest was 0.05. And the median was 0.26.

RDY's Debt-to-Equity is ranked better than
77.08% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs RDY: 0.07

Dr Reddy's Laboratories Debt-to-Equity Historical Data

The historical data trend for Dr Reddy's Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

0.27

0.14

0.18

0.06

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.08	0.06	0.05	0.05	0.07

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Debt-to-Equity falls into.

Dr Reddy's Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dr Reddy's Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(148.226	+	15.535)	/	2807.838
	=	0.06

Dr Reddy's Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(164.545	+	73.894)	/	3217.263
	=	0.07

Dr Reddy's Laboratories (NYSE:RDY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dr Reddy's Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Debt-to-Equity

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.